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Abstract
Background: Bacterial vaginosis (BV) during pregnancy is associated with an increased risk of
preterm delivery but little is known about factors that could predict BV. We have analyzed if it is
possible to identify a category of pregnant women that should be screened for BV, and if BV would
alter the pregnancy outcome at term; we have also studied the treatment efficacy of clindamycin.
Methods: Prospective BV screening and treatment study of 9025 women in a geographically
defined region in southeast Sweden. BV was defined as a modified Nugent score of 6 and above.
Data was collected from the Swedish Medical Birth Register. Women allocated to treatment were
supplied with vaginal clindamycin cream. The main outcome goals were to identify factors that
could predict BV.
Results: Vaginal smears were consistent with BV criteria in 9.3%. Logistic regression indicates a
significant correlation between smoking and BV (p < 0.001) and a greater prevalence of BV in the
lower age groups (p < 0.001). We found no correlation between BV and history of preterm
deliveries, previous miscarriages, extra-uterine pregnancies, infertility problems or reported
history of urinary tract infections–factors that earlier have been associated with BV. Treatment
with clindamycin cream showed a cure rate of 77%. Less than 1% of women with a normal vaginal
smear in early pregnancy will develop BV during the pregnancy. There was no association between
BV and the obstetric outcome among women who delivered at term. Women with BV, both
treated patients and nontreated, had the same obstetric outcome at term as women with normal
vaginal flora.
Conclusion: BV is more than twice as common among smokers, and there is a higher prevalence
in the younger age group. However these two markers for BV do not suffice as a tool for screening,
and considering the lack of other risk factors associated with BV, screening of all pregnant women
might be a strategy to follow in a program intended to reduce the number of preterm births.
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Background
Bacterial vaginosis (BV) is one of the most common vagi-
nal infections with prevalence among pregnant women
between 10 and 20% [1-3]. There is an association
between BV and preterm delivery [1,2,4-6] and also
between BV and early spontaneous miscarriage prior to 16
weeks gestation [7]. Associations between BV and urinary
tract infections (UTI) [8,9] as well as between BV and his-
tory of infertility caused by tubal factors [10] have been
reported in other studies. There is also an association
between smoking and BV [11-14].
The primary outcome is to determine the presence of pre-
disposing factors which might be identified at the first
antenatal visit and thus reduce the number of women
potentially at risk for BV requiring treatment. The second-
ary outcome were the efficacy of clindamycin treatment
during pregnancy and if there are any other associations
on the obstetric outcome among term deliveries and BV.
Methods
All gravida who were booked for antenatal care at clinics
in southeast Sweden between February 1999 and May
2001 were invited to take part in an intervention study to
investigate whether treatment of BV with clindamycin
cream could reduce the frequency of preterm delivery and
the morbidity of preterm infants. The result from the latter
study has been published [15] and showed that treatment
of BV with clindamycin was associated with significant
prolongation of gestation with 32 days among women
with late miscarriage or preterm delivery. The study at
hand is an analysis of the same patient population. A vag-
inal smear was taken at the first antenatal visit and graded
for BV according to Nugent with the exception that a
Nugent score of 6 was defined as BV as discussed earlier
[15-17].
We used modified Nugent scoring for the diagnosis of BV
as we earlier encountered limitations in the use of Nugent
scoring. This particularly applies to treatment studies and
is even more pronounced when clindamycin vaginal
cream is the selected treatment.
At the first antenatal visit, all women were interviewed
regarding occupation, civil status, medical history, earlier
pregnancies, fertility problems, alcohol, medication, his-
tory of UTI, and smoking habits (nonsmokers, smoke 1–
9 cigarettes per day or smoke 10 or more cigarettes per
day); the latter responses defined smoking habits 3
months prior to conception and the prevailing situation at
the first antenatal visit. This information was registered in
the antenatal medical record. After delivery, all data col-
lected during the pregnancy, delivery and early puerperal
period was sent to the Medical Birth Register (MBR) at the
Swedish National Board of Health and Welfare. The study
compared MBR data with the status of the vaginal smears.
However if a gravida had a termination of pregnancy or a
spontaneous abortion prior to 22 weeks gestation, or a
intrauterine death between 22–28 weeks gestation no
such data is available from MBR.
The women participated in a randomized consent design
treatment study according to Zelen [18] which investi-
gated the outcome of treatment with vaginal clindamycin,
or alternatively no treatment, on early preterm birth. All
women with BV were randomized to either an interven-
tion group with a 7-day regimen of treatment with clin-
damycin vaginal cream or a control group to remain
untreated and uninformed of their BV status as stipulated
in the pre-randomized consent design for clinical trials.
Only women who were diagnosed with BV and rand-
omized to the intervention group were informed of the
status of their vaginal smear. Data from the frequency of
preterm delivery is published [15]. Evaluation of treat-
ment efficacy was done with new Gram-stained smears
both 12 and 20 weeks after treatment. The treatment
results were classified cured, improved, or failure. Cured
meant the smear had a Nugent score of < 4 or a Hay/Ison
score of 1 [2,19], improved meant the Nugent score was
4–5 or Hay/Ison score was 2, and treatment failure indi-
cated that the Nugent score was ≥ 6 or Hay/Ison score was
3. The women from the randomized control study are
included in the analysis.
The study has been approved by the Regional Ethics Com-
mittee in Linköping, Sweden and the Medical Products
Agency in Sweden.
Statistics
Statistical analysis with Chi-square test, Odds Ratio (OR)
with 95% Confidence Interval (CI) and logistic regression
were done using the SPSS program for Windows version
14.0.
Results
We analyzed the same patient population that was used in
our treatment study [15], thus a total of 9025 women
were screened for BV during their first antenatal visit. After
exclusion of women who were lost or had terminated
pregnancies, the study comprised 8791 women (Figure 1).
Evaluation of Gram-stained vaginal smears revealed a
prevalence of BV of 9.3%. A higher rate of BV is found in
the age group 18–25. The mean age among the women
with normal smears was 29.2 versus 28.6 among women
with smears indicating BV (p = 0.001, student t-test) (Fig-
ure 2).
The percentage of women reporting that they were smok-
ers three months prior to conception was 21.0% (1715/BMC Women's Health 2007, 7:20 http://www.biomedcentral.com/1472-6874/7/20
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8168) (missing data for 623 women). The percentage of
women reporting being smokers at the time of the first
antenatal visit was 11.8% (983/8351) (missing data for
440 women). Seven hundred and fifty-nine women
stopped smoking when they learned they were pregnant
and only nine women took up smoking during early preg-
nancy.
A greater percentage of smokers are found among women
with BV. Three months before pregnancy, 36.4% of the
women with BV were smokers compared to 19.4% among
the women who had normal vaginal smears (OR 2.4 95%
CI 2.0–2.8). Corresponding data supplied at the first ante-
natal visit indicates 23.4% smokers among BV patients
compared to 10.6% among those with normal vaginal
smears (OR 2.6 95% CI 2.2–3.1). At the first antenatal
visit, the OR was 2.2 to smoke 1–9 cigarettes/day com-
pared to OR 3.0 to smoke ≥ 10 cigarettes/day. (Table 1)
Women who had stopped smoking just prior to preg-
nancy or in an early stage (n = 759) had a higher preva-
lence of BV than those who had never smoked. The
prevalence of BV was 18.4% among women who were
smokers both before and during early pregnancy, 13.2%
in women who had stopped smoking and 7.6% among
patients who had never smoked.
We found no correlation between BV in early pregnancy
and self-reported miscarriages (19.6% in both groups),
infertility more than 1 year before the actual pregnancy,
infertility surgery, extra-uterine pregnancies or in vitro fer-
tilization. We found no association between BV and dia-
betes, self-reported history of repeated urinary tract
infections (UTI) or maternal underweight.
Of the participating women, 43.5% were primiparous and
had BV in 9.7% compared to 8.9% for multiparous
women. Multiparous women with BV included in this
study did not report a higher frequency of previous pre-
term birth than women who at inclusion had a normal
vaginal flora (7.8% vs. 8.6%). (Table 2)
Binary multiple logistic regression analysis showed signif-
icant correlation between BV and smoking (OR 2.53 95%
CI 2.11–3.04, p < 0.0001) and BV and women in the
younger age groups, i.e. under 26, (OR 0.97 95% CI 0.96–
0.99, p < 0.001), even though both smoking and BV are
more common in the younger age groups (Figure 2). The
frequency of BV among nonsmokers is 14.5% in the age
group 18–21, compared to 8.0% in the age group >35.
There is a significant declining frequency of BV with increas- ingage among nonsmokers Figure 2
There is a significant declining frequency of BV with increas-
ingage among nonsmokers. (OR for each age group are 0.83 
(95% CI 0.75–0.90) but among smokers, the OR are 1.03 
(95% CI 0.89–1.20). Women >40 yrs. of age who are smok-
ers have a high percentage of BV, but this age group has a 
small population (of 9 women, only were 3 smokers).
Flow chart of the participation status in the preterm delivery  study Figure 1
Flow chart of the participation status in the preterm delivery 
study. At start there were 9025 women and 8791 remained 
throughout the study.
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A total of 408 women were randomized to treatment
(with clindamycin cream) at a mean gestational week of
12+ 6, and of these 332 contributed a second smear at a
mean time of 12.5 weeks later (gestational week 25+ 3).
There is a 15% difference in cure rate depending on the
classification used: Nugent score [16] or Hay/Ison [2,19].
According to Nugent scoring there were 63% cured and
22% improved and 15.4% treatment failure, whereas
according to Hay/Ison 77% were cured, 12% improved,
and 10% treatment failures.
A total of 463 women not receiving treatment were fol-
lowed-up with a second smear after 10–12 weeks (at the
mean gestational week 24). Of the 443 women who did
not have BV at the first antenatal visit, only 4 (0.9%) had
developed BV during the pregnancy.
Analysis of the outcome of the pregnancies did not show
any association between BV and poor obstetric outcome
nor did we find any association to instrument or Cesarean
delivery, preeclampsia, or early rupture of the membranes
whether or not any treatment with clindamycin was given.
There was no association between the presence of BV and
infant characteristics such as gender, small for gestational
age (SGA) or asphyxia. Treatment of BV did not increase
the risk for having preeclampsia (OR 1.1 95% CI 0.6–2.2).
Of 392 treated women, 4.2 percent had preeclampsia
compared to 4.6% of the non-treated women (Table 3).
Discussion
This study of factors that predict BV during pregnancy is
one of the most comprehensive ever published and is
based on around 9000 pregnant women. We found that
smoking is strongly associated with BV as indicated by at
least a doubled prevalence of BV among smokers as com-
pared to nonsmokers. This has been shown by others [11-
14] and there are several possible explanations. The first is
that smoking does indeed have a causal connection to BV,
the second is that women who smoke may have a risk
behavior that would predispose to BV, and the third is
that women who smoke may not notice the malodor
caused by BV. As we could demonstrate that BV in early
pregnancy is more common among women who have
stopped smoking compared to women who had never
smoked, there might be a causal connection between BV
and smoking. Nicotine in the vagina/cervix could have a
negative impact on vaginal flora. To our knowledge, our
study is the first to indicate that BV is more common
among women who are former smokers than among
those who have never smoked.
We also found that BV did not increase with increasing age
as suggested earlier [20] a supposition which is very com-
monly quoted in reviews of BV. The frequency of BV in
our study was 16% in the age group 18–21 years com-
pared to 8% in the age group 31–35 years (Fig 2). The
often quoted studies come from different populations
Table 2: Self-reported medical history obtained at the first antenatal visit
BV No BV Missing
Yes All BV % Yes All No BV % Total
Earlier miscarriages 156 795 19.6 1534 7821 19.6 175 OR 1.0 (95% CI 0.8–1.2) 8791
Infertility more than 1 year 49 795 6.2 551 7821 7.0 175 OR 0.9 (95% CI 0.6–1.2) 8791
Infertility surgery 2 795 0.3 16 7821 0.2 175 OR 1.2 (95% CI 0.3–5.4) 8791
Extrauterine pregnancy 8 795 1.0 113 7821 1.4 175 OR 0.7 (95% CI 0.3–1.4) 8791
In vitro fertilizations 1 795 0.1 54 7821 0.7 175 OR 0.2 (95% CI 0.03–1.3) 8791
UTI 109 795 13.7 1192 7821 15.2 175 OR 0.9 (95% CI 0.5–1.5) 8791
Previous preterm birth 34 402 8.5 383 4444 8.6 0 OR 0.9 (95% CI 0.6–1.3) 4846
Diabetes 1 795 0.1 18 7821 0.2 175 OR 0.5 (95% CI 0.1–4.0) 8791
BMI underweight 17 752 2.3 145 7321 2.0 718 OR 1,1 (95% CI 0.7–1.9) 8791
Table 1: Correlation between smoking and BV
BV No BV Missing
Yes All BV % Yes All No BV % Total
Smoker 3 mos. before 1st visit 278 764 36.4 1437 7404 19.4 623 OR 2.4 (95% CI 2.0–2.8) * 8791
Smoker at 1st antenatal visit 181 774 23.4 802 7577 10.6 440 OR 2.6 (95% CI 2.2–3.1) * 8791
Smoker 1–9 cig/day at 1st visit 116 774 15.0 575 7577 7.6 440 OR 2.2 (95% CI 1.8–2.7)* 8791
Smoker >10 cig/day at 1st visit 65 774 8.4 227 7577 3.0 440 OR 3.0 (95% CI 2.2–3.9) * 8791
* p < 0.05BMC Women's Health 2007, 7:20 http://www.biomedcentral.com/1472-6874/7/20
Page 5 of 6
(page number not for citation purposes)
such as sexually transmitted disease clinics. The fact that
BV prevalence increases with age has been used as an argu-
ment that BV is not a sexually transmitted infection (STI)
as other STIs are more common among younger women
[21].
We used modified Nugent scoring for the diagnosis of BV
[15,17] as we earlier encountered limitations in the use of
Nugent scoring. This particularly applies to treatment
studies and is even more pronounced when clindamycin
vaginal cream is the selected treatment. Clindamycin vag-
inal cream eradicates almost all bacteria in the vagina, and
greatly reducing the lactobacilli morphotype bacteria and
giving the Nugent score of around 4. This means that the
smear can be incorrectly interpreted as demonstrating
intermediate flora. On the other hand if there are only five
gardnerella morphotype bacteria per vision field, the
Nugent score would increase from 0 to 3 even when there
are more than 500 lactobacilli morphotype bacteria [17].
The Hay/Ison [2,19] classification is better adapted to fol-
low-up treatment results, and for this reason we have
deliberately expressed the efficacy in two different ways
showing a 15% difference in efficacy depending on the
evaluation method used. This has to be taken into consid-
eration when discussing treatment efficacy.
Our study also indicates that there is a less than 1% risk of
developing BV among women whose early screening
shows normal lactobacilli flora. A similar finding has
been reported earlier [22,23].
Therefore we conclude that one BV screening in early preg-
nancy will suffice to identify women with increased risk
for BV and thus also preterm birth.
Despite the comprehensive scope of this study, we could
not demonstrate any correlation between the presence of
BV and previous miscarriage, infertility, extra-uterine
pregnancies or recurrent UTI, factors that other studies
have associated with BV [8-10]. We found no association
to adverse pregnancy outcome between the women with
normal lactobacilli or BV. Ugwumadu et al. found a non-
significant trend for an association between pre-eclampsia
and treatment with clindamycin [4] but we could not ver-
ify this even though we had 340 preeclampsia patients in
our material. Only women who delivered were included
in our study, otherwise no supplementary data would be
available from MBR. The fact that we studied only preg-
nant women might be a selection bias since infertile
women were not included. Ralph et al. reported that BV
during pregnancy predisposed to an increased rate of very
early miscarriages after assisted fertilization [24], a cir-
cumstance we can not demonstrate in our study, and this
might explain why we found no correlation between BV
and earlier miscarriages. Ours is the first study to show
that there are no increased risks for poor obstetrical out-
come in term pregnancies even if the women are infected
by BV.
Conclusion
The conclusion from this study is that there are no factors,
based on the interview answers given at the first antenatal
visit, that could predict the presence of BV and that selec-
tive screening based on this type of data gathering is not
possible. The only alternative would be to screen all preg-
nant women. Smoking habits influence the risk for
women to acquire BV. As both smoking and BV in turn
increase the risk for late miscarriage, preterm rupture of
the membranes, and preterm delivery, both factors
(smoking and BV) ideally should be eliminated during
pregnancy. To screen for BV, only one vaginal sample is
required, and if this is consistent with normal vaginal
flora, there is no need to take another smear during preg-
nancy as the risk of developing BV is less than 1%.
Table 3: Obstetrical outcome among BV patients after treatment with clindamycin
Obstetric outcome BV No BV Missing
Effect of treatment Yes All BV % Yes All No BV % Total
Instrument delivery 64 816 7.8 631 7945 7.9 30 OR 1.0 (95% CI 0.8–1.3) 8791
Treated BV vs. not treated BV 34 407 8.4 OR 0.9 (95% CI 0.6–1.3) 816
Cesarean delivery 107 816 13.1 1124 7945 14.1 30 OR 0.9 (95% CI 0.7–1.1) 8791
Treated BV vs. not treated BV 52 407 12.8 OR 0.9 (95% CI 0.7–1.3) 816
Preeclampsia 36 816 4.4 304 7945 3.8 30 OR 1.2 (95% CI 0.8–1.7) 8791
Treated BV vs. not treated BV 17 407 4.2 OR 1.2 (95% CI 0.7–1.9) 816
Early rupture of membranes 43 816 5.3 391 7945 4.9 30 OR 1.1 (95% CI 0.8–1.5) 8791
Treated BV vs. not treated BV 24 407 5.9 OR 0.9 (95% CI 0.6–1.5) 816
SGA 49 815 6.0 374 7920 4.7 56 OR 1.3 (95% CI 0.95–1.8) 8791
Treated BV vs. not treated BV 21 407 5.2 OR 1.4 (95% CI 0.98–2.2) 815
5 min. 22 819 2.7 191 7972 2.4 0 OR 1.1 (95% CI 0.7–1.8) 8791
Treated BV vs. not treated BV 7 407 1.7 OR 1.5 (95% CI 0.9–2.6) 819
Gender = Female 379 815 46.5 3846 7933 48.5 43 OR 0.9 (95% CI 0.8–1.1) 8791BMC Women's Health 2007, 7:20 http://www.biomedcentral.com/1472-6874/7/20
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